LLY ELI LILLY & Co
Company Analysis
Latest News
Eli Lilly's fourth quarter 2025 revenue surged 43% to $19.3 billion, driven by blockbuster sales of Mounjaro and Zepbound.
Eli Lilly reported fourth quarter 2025 revenue of $19.3 billion, a 43% increase year-over-year, driven by strong volume growth. Non-GAAP earnings per share...
Eli Lilly Surges 7% Pre-Market on Tirzepatide Optimism and 31% EPS Growth Forecast
Eli Lilly shares rose 7.18% in pre-market trading on February 4, 2026. The stock reached a price of $1075.49. This follows a close of $1003.46 on February 3....
FDA Extends Review Timeline for Eli Lilly's Oral Obesity Drug Orforglipron
The U.S. Food and Drug Administration (FDA) extended the review period for Eli Lilly's oral GLP-1 weight-loss candidate, orforglipron. The new expected...
Eli Lilly Faces Competitive Headwinds as Oral Obesity Drug Orforglipron FDA Decision is Delayed
Eli Lilly is facing increased competitive pressure in the oral GLP-1 market after the FDA delayed the decision date for its candidate, orforglipron, causing...
Eli Lilly Stock Rises on FDA Obesity Drug Approval Momentum; Valuation Concerns Persist
Eli Lilly shares surged 3.58% to close at $1,078.52, driven by strong investor optimism surrounding the company's leading GLP-1 obesity drug portfolio...
🟢 Eli Lilly is trading 3% up today with market rebound
LLY is trading at $1074 (+3.14%) amid a broader market rebound following yesterday's tariff-driven selloff. Major indices are up modestly (S&P 500 +0.30%,...
Eli Lilly's Oncology Pipeline Receives Major FDA Breakthrough Therapy Designation
Eli Lilly received a significant boost after the U.S. FDA granted Breakthrough Therapy Designation (BTD) to a novel oncology candidate, aiming to fast-track...
Eli Lilly holding steady amid FDA Breakthrough Therapy designation for sofetabart mipitecan and broader market decline
Eli Lilly announced that its investigational drug, sofetabart mipitecan, received FDA Breakthrough Therapy designation for the treatment of platinum-resistant...
Lilly's Ovarian Cancer Drug Candidate Receives FDA Breakthrough Therapy Designation
Eli Lilly and Company announced the FDA granted Breakthrough Therapy designation to its investigational drug, sofetabart mipitecan. The designation targets...
Lilly's Ovarian Cancer Drug Candidate Receives FDA Breakthrough Therapy Designation
Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for its drug candidate, sofetabart...
Eli Lilly announces FDA Breakthrough Therapy designation for sofetabart mipitecan in pre-market
Eli Lilly announced that the FDA granted Breakthrough Therapy designation to its investigational drug, sofetabart mipitecan (LY4170156), for the treatment of...
Eli Lilly Solidifies Lead in Weight-Loss Drug Market Amid Fierce Competition
Eli Lilly is extending its lead over Novo Nordisk in the rapidly growing weight-loss drug market. Analysts cite the superior effectiveness of Lilly’s Zepbound...
Eli Lilly Shares Plunge Nearly 5% to Hit Four-Week Low Amid Sharp Selling Pressure
Eli Lilly shares suffered a sharp decline on January 15, falling by as much as 4.87% despite overall U.S. markets advancing during the session. The stock...
🔴 Eli Lilly is trading 3% down today after FDA delayed decision on weight-loss pill
Eli Lilly is trading at $1041.07 (-3.00%) after the FDA announced a delay in the decision timeline for its weight-loss pill. * The FDA decision on the drug...
Eli Lilly Shares Decline After FDA Delays Decision on Oral Weight-Loss Pill
The U.S. Food and Drug Administration (FDA) delayed its decision on Eli Lilly’s new oral weight-loss pill. The agency set a new target date of April 10,...
BMO Capital Markets Reiterates 'Buy' Rating on Eli Lilly, Citing Strength in Weight-Loss and Pipeline
BMO Capital Markets reaffirmed its 'outperform' rating on Eli Lilly (LLY). The firm set a $1,200 price target, suggesting a 12% upside from current...
Eli Lilly CEO Highlights Positive Outlook at JPMorgan Healthcare Conference
Eli Lilly CEO Dave Ricks presented at the JPMorgan Healthcare Conference. The transcript became available on January 14, 2026. Ricks set a positive tone for...
Eli Lilly and Nvidia Announce $1 Billion AI Collaboration for Drug Discovery
Eli Lilly and Nvidia launched a collaboration focused on applying advanced artificial intelligence (AI) to drug development. The initiative is backed by a...
Eli Lilly CFO Confirms Q2 2026 Target for FDA Approval of Oral Obesity Pill Orforglipron
Eli Lilly CFO Lucas Montarce confirmed the company's timeline for its oral obesity drug, orforglipron, at the JPMorgan Healthcare Conference. Lilly targets...
Eli Lilly and Nvidia Announce $1B AI Lab for Drug Discovery
Eli Lilly and Nvidia announced a major collaboration to launch an artificial intelligence co-innovation lab. Unveiled at the J.P. Morgan Healthcare Conference,...